ArticleClinical & translational immunology2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections.
Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV-related cervical disease to reduce the number of new cancer cases and associated deaths. Methods: We previously reported that replication-deficient adenovirus type 26 and 35-based vectors (Ad26, Ad35) expressing a fusion protein of E2, E6 and E7 (E2SH) from HPV16 and HPV18 induced robust HPV-specific T-cell immunity capable of reducing HPV16+ tumors in mice. Here, we assessed immune responses induced by Ad26 and Modified Vaccinia Virus Ankara-strain Bavarian Nordic (MVA-BN) viral vectors expressing E2SH in heterologous vaccination regimens in mice, macaques and a limited number of persistently HPV-infected women ( Results: The magnitude and breadth of cellular immune responses were higher in mice that received Ad26.HPV16/18-MVA-BN.HPV16/18 than in those that received Ad26.HPV16/18-Ad35.HPV16/18, all expressing the fusion protein E2SH of HPV16 and HPV18. Sustained and broad antigen-specific systemic T-cell responses against HPV16 and HPV18 proteins were induced in macaques. In the Phase 1/2a trial, a 2-dose heterologous immunisation with Ad26.HPV16 or Ad26.HPV18 in Week 0 and MVA-BN.HPV16/18 in Week 8 induced long-lived antigen-specific cytokine-producing T cells. After Week 8, HPV16/18 infection was no longer detected in 5/5 active vaccines and 1/4 placebo recipients during the study period of approximately 1 year. The small number of vaccinated participants did not allow concluding on the relationship between immune responses and viral clearance. Conclusion: These data show the ability of Ad26.HPV16/18-MVA-BN.HPV16/18 heterologous regimens to elicit HPV-specific T-cell responses and warrant further clinical studies to evaluate vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.